Our Partners


CHS on facebook and YouTube


Karttik Shah Youth Fellowship - Deadline: November 27, 2015

The CHS Karttik Shah Youth Fellowship was initiated in memory of Karttik Shah of Toronto, Ontario, in recognition of his commitment to hemophilia youth programming in Canada and abroad, and, in particular, for his participation over many years on the CHS Board of Directors and the World Federation of Hemophilia Youth Committee. In order to promote the development of its future leaders, the CHS will offer one or more fellowships to enable  Canadian youth who are committed to long-term involvement in the CHS to attend the Hemophilia 2016 World Congress taking place in Orlando, Florida, July 24-28, 2016.

A complete application form must be received by the CHS by 5 p.m. EST November 27, 2015.

Please CLICK HERE for more details.

Products in the pipeline - NEW UPDATE (November 17, 2015)

Never have so many clotting factor concentrates been in development or “in the pipeline”. So many, in fact, that it has become difficult to keep track of them all. So the CHS is publishing five charts, one each for factor VIII, factor IX, inhibitor products, other coagulation products, and one for factor VIII, IX and other rare bleeding disorders together, to help everyone stay informed of their progress through preclinical work, clinical trials and regulatory approval.

Click here for more details.

Hemophilia Today - November 2015

UPDATED CHS resource about HCV treatment support for 1986-1990 claimants

Accessing treatments for hepatitis C through the Hepatitis C January 1, 1986 — July 1, 1990 Class Actions Settlement: What you need to know

If you are a patient who received tainted blood or blood products and a registered claimant of the Hepatitis C (HCV) 1986-1990 Class Actions Settlement, now is a good time to speak to your doctor about new treatments for HCV. Treatment has progressed significantly, and it may be the right time for you to seek a cure.

People who are approved claimants under the Hepatitis C January 1, 1986 — July 1, 1990 Class Actions Settlement may be reimbursed for their costs for treatments and generally accepted hepatitis C medications that are not recoverable under any public or private health care plan. Many companies that make and sell hepatitis C medications have programs to support patients throughout treatment.These programs offer assistance by providing drugs upfront to the 86-90 claimants through their specialty pharmacy. Once the 86-90 plan issues the reimbursement cheques to the patients for their treatment, they, in turn, must reimburse the pharmacy directly.

Because this is not well known by the claimants themselves nor their health care providers, the CHS has developed a new resource to provide more information. Note that the resource was recently updated to include new and additional patient support programs.

Please click here for more information and access to the new brochure.

CHS support to research and market studies

Several times in the past, the CHS has invited the bleeding disorder community to participate in research and market studies. Once again, we wish to reinforce the importance of these projects and the benefit for our community to participate. Research and market studies are crucial to the advancement of care and treatment. This is your chance to voice your concerns and priorities when it comes time to your care and treatment or those of your child. At many levels, these studies are often one step closer towards a better quality of life.

These studies, however, need our community to gather sufficient data to be relevant.

Please take the time to see what is presently happening with regards to research and market studies and to see if you could take an active part in them.

Click here for more details on the RESEARCH studies currently recruiting participants.


Click here for more details on the MARKET studies currently recruiting participants.

CHS recommendations on use of surplus in the Trust Fund of the 86-90 Hepatitis C Settlement Agreement

Please click here to download the recommendations the CHS sent to the members of the Joint Committee of the 1986-1990 Hepatitis C Settlement Agreement so that they may consider them for inclusion in the application that they will make to the Courts on how the surplus should be used.

Webcast - Rendez-vous 2015

A Webcast of the Rendez-vous 2015 presentations from the Medical and Scientific Symposium (May 29, 2015) is now available on YouTube.

Click here to access the appropriate links for each session.

End of CHS / AHCDC / CSL Behring Hemostasis Fellowship Program

It is with regret that the CHS is announcing the end of the CHS / AHCDC / CSL Behring Hemostasis Fellowship Program which has been in existence since 2001. The CHS wishes to thank CSL Behring for its continued support of this program since 2010 which provided many fellows in hematology or other relevant fields the opportunity to obtain additional focused clinical or research training relevant to hemostasis.

Penny wise, pound foolish - The national clinic assessment

In 2013‐14, the Canadian Hemophilia Society (CHS) conducted an assessment of the human
and physical resources in the network of 25 Inherited Bleeding Disorder Comprehensive Care
Centres (IBDCCCs) across Canada. The staff in these Centres care for the vast majority of
Canadians with inherited bleeding disorders. Our goal was to evaluate their capacity to
respect current national Standards of Care. Individual reports were provided to each
Program’s Centre Director.

A national report was presented on May 28, 2015, at Rendez-vous 2015, in Halifax.

Click here to read the full report.

Menstrual Assessment Chart (PBAC)

Important documents updated

The CHS has recently updated five widely consulted informative documents on three related topics:

  • access to insurance (life, mortgage, travel, health insurance for overseas students, group) for people with bleeding disorders;

  • an overview of the different compensation programs for blood-borne HIV and HCV infection created since 1989.

Please click on the links above to access the revised documents.

A bandage is not enough.


Click here for more information about this important public awareness and outreach campaign or to download promotional material.

E-novella spreading the word on bleeding disorders on Wattpad

One in 100 Canadians carries an inherited bleeding disorder gene, yet so many remain undiagnosed. In an effort to educate a younger audience about the symptoms and risks of bleeding disorders, we’ve developed an e-novella – entitled ‘A Negative’ – to spread the word in an engaging and memorable way.

Playing off the popular Harlequin romance genre, ‘A Negative’ tells the story of a young woman unknowingly living with von Willebrand disease. We’ve published the e-novella on Wattpad – the world’s largest online community of writers and readers – in order to connect with young women across Canada. This unique approach introduces the issue into a different medium, enabling us to speak to and educate an engaged but unsuspecting audience.

CLICK HERE for the press release.

CLICK HERE to read 'A Negative'.

You and your family depend on research...

Make a difference - Help save lives

We can stop the suffering of those living with hemophilia and other bleeding disorders. But we can't do it alone. Only with the generous financial support of caring Canadians can we make our dream come true.

To support us